GPS - SELLAS Life Sciences announces IDMC's recommendation of continuing REGAL phase 3 study without modifications
2024-04-29 08:54:27 ET
More on SELLAS Life Sciences
- Sellas Life Sciences Group: A Lottery Ticket With An Estimated 6x Payout
- SELLAS Life Sciences GAAP EPS of -$1.34 misses by $0.24
- SELLAS Life Sciences looks to raise $20M in a direct offering
- Seeking Alpha’s Quant Rating on SELLAS Life Sciences
- Historical earnings data for SELLAS Life Sciences